newsThe $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin…
17 May 2022 | By European Pharmaceutical Review
The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin gene-related peptide (CGRP) programmes, including migraine treatment rimegepant.